Abstract: Interest in dietary supplements and their efficacy in treating and preventing disease has increased greatly since the outbreak of the COVID-19 pandemic. Due to the risk of severe COVID-19 in patients with cancer, we conducted a narrative review aiming to better understand the data on the safety of the most efficacious “anti-COVID-19” nutraceuticals for patients with cancer. We conducted a PubMed database search aimed at identifying the most effective nutrients for use against COVID-19. For the identified nutraceuticals, we searched PubMed again regarding their safety for patients with cancer. Fifty-four total records (52 independent studies) were retrieved, pertaining to vitamin D, vitamin C, selenium, omega-3 fatty acids, and zinc. Vitamin D results from 23 articles indicated safe use, but two articles indicated potential harm. All 14 articles for vitamin C and five out of six articles for selenium indicated the safety of use (one study for selenium suggested harm with high-dose supplementation). Results for omega-3 fatty acids (seven articles) and zinc (one article), however, were rather mixed regarding safety. We conclude that vitamin D, vitamin C, and selenium supplements are likely safe or even beneficial at typically recommended doses; however, caution is urged with omega-3 fatty acid supplements, and zinc supplements should likely be avoided. More experimental research is needed, and nutraceutical use by patients with cancer should always be under the supervision of a healthcare team.

Keywords: cancer; nutraceuticals; supplements; COVID-19; SARS-CoV-2

1. Introduction

In December 2019, a novel virus of unknown etiology was detected in Wuhan, China [1]. The virus, which most often manifests as a severe respiratory syndrome, quickly spread from Wuhan, with cases appearing globally by 30 January 2020 [2]. It was quickly labeled by the World Health Organization as a public health outbreak of international concern and was later declared a pandemic [2,3]. This novel airborne pathogen, since named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes the disease now known as COVID-19 [2]. Despite containment efforts and the introduction of a vaccine in late 2020, by November 2021, over 5 million deaths had been attributed to the virus [4].
COVID-19 has been shown to manifest heterogeneously across different patient populations. Mild cases often result in flu-like symptoms, fever, or loss of taste and smell [5]. However, in severe cases, the effects of infection are more significant, resulting in an abnormal cytokine and chemokine response that causes systemic inflammation, affecting multiple tissues and organ systems [6]. Individuals with co-morbidities such as obesity, diabetes, cardiovascular disease, and cancer have a greater tendency to elicit this cytokine storm, making infection with COVID-19 particularly dangerous for these at-risk subgroups of the population [7–11].

Accordingly, attention has focused on protecting these vulnerable individuals, as well as the general public, from infection. However, the lack of efficacious pharmacological treatments for COVID-19 has led the public to seek alternative therapies, including nutraceuticals [12,13]. Nutraceuticals are foods or substances derived from food that may have a physiological effect or protect against disease. They have received heightened interest as some may affect the severity of COVID-19. For example, several observational studies have been published describing the association between specific nutrient deficiencies and COVID-19 severity and mortality [14,15]. A review by Vassiliou et al., which examined the role of vitamin D status in predicting outcomes in critical illness, concluded that there is an association between insufficient vitamin D status and infection, severity of illness, and mortality from COVID-19 [16]. Another review by Lordan et al. found an association between zinc deficiency and increased COVID-19 complications [17]. In vivo studies have also pointed to the role of nutraceuticals in the treatment and prevention of COVID-19, including a study by Corrao et al., which demonstrated an inverse relationship between C-reactive protein (CRP), a marker of systemic inflammation, and supplementation with vitamin C, vitamin D, and zinc [18]. Furthermore, there have been several theoretical papers discussing the potential mechanistic roles of nutraceuticals and how they might target the SARS-CoV-2 virus [19–21]. For example, for probiotics, one of the proposed mechanisms is by acting as angiotensin-converting enzyme (ACE) inhibitors, preventing SARS-CoV-2 from binding to ACE receptors in gastrointestinal cells [22]. For the keto-carotenoid astaxanthin (a terpene), it has been suggested that it may play a role in regulating reactive oxygen species formation, and therefore, supplementation may inhibit oxidative stress caused by SARS-CoV-2 [23]. Additionally, immunomodulatory nutraceuticals, such as glycophosphopeptide AM3, may be beneficial as either prophylactic or adjuvant therapy for SARS-CoV-2, as they improve the efficacy of action of natural killer cells and increase the production of anti-inflammatory cytokines [24]. While the use of most of these nutraceuticals is advocated on the basis of in vitro and in vivo observations for other similar viruses (e.g., SARS-CoV and MERS-CoV), there is a growing number of observational studies and randomized controlled trials (RCTs) specifically for COVID-19 that point to the potential efficacy of nutraceuticals in the fight against this novel pathogen.

The potential use of nutraceuticals for the supportive treatment of COVID-19 is particularly relevant and promising for those who are more susceptible to both infection and a severe course of the disease. Patients with cancer, in particular, may be at high risk of severe disease and mortality from COVID-19 depending on their disease stage, treatment, and type of cancer [25]. Generally speaking, there are numerous mechanisms behind the increased risk of COVID-19 infection in these patients, including immunosuppression from cancer therapy and immunosuppression from cancer itself [26]. Chemotherapy, which limits the growth of cancer cells, also impacts the production of white blood cells, leaving patients more susceptible to infection [27]. Patients with late-stage cancer are also at increased risk of infection as bone metastases can trigger an immune response that leads to bone marrow aplasia, resulting in a reduction of white blood cells, red blood cells, and platelets, which again leaves these individuals vulnerable to worse outcomes if infected with COVID-19 [28]. Additionally, patients with cancer tend to be older and have more co-morbidities, putting them at risk of a severe course of disease with COVID-19 [26].

It is therefore not surprising that the COVID-19 pandemic also resulted in increased fear and worsened anxiety and depression associated with a cancer diagnosis [29]. As
such, many individuals, immunocompromised and healthy alike, have sought out ways to improve immunity [30]. Concurrently, popular media outlets have promoted the use of a variety of dietary supplements with putative immune-boosting potential that may help against COVID-19 infection [31,32]. This has led to a major increase in dietary supplement use during the pandemic, with a roughly 35% increase in North and South America, a 40% increase in Asia, and a 38% increase in Europe [30,33]. Concerningly, only 40% of these individuals consume supplements at the recommendation of a licensed medical professional [30].

Increased supplement use during the COVID-19 pandemic, especially without appropriate medical supervision, is troubling for oncologists and other oncology specialists. Specifically, one concern relates to the potential dampening of the cytotoxicity of chemotherapy by antioxidants and other supplements. The Diet, Exercise, Lifestyle, and Cancer Prognosis (DELCaP) study, a correlative study to the phase III SWOG SO221 [34], examined supplement use in patients with breast cancer and survivorship. This study found that the use of any antioxidant supplements, before or during breast cancer treatment, was associated with an increased risk of breast cancer recurrence and that vitamin B12 use during treatment was associated with poorer survival rates and poorer disease-free survival [34]. Results such as these indicate that nutraceutical use during or around chemotherapy may not be benign.

Given the rise in oral supplement use during the COVID-19 pandemic, as well as the increased interest in the efficacy of nutraceuticals in preventing or reducing the severity of COVID-19, we conducted a narrative review focusing on the safety of the most efficacious “anti-COVID-19” oral supplements for patients with cancer. As COVID-19 is still a present threat, individuals with cancer and their providers need up-to-date, evidence-based guidance for supplement use around their respective treatments.

2. Methods

We conducted our initial literature search on 8 September 2021 focusing on the efficacy of nutraceuticals for the treatment and prevention of COVID-19. We performed the search in the PubMed database and included variations of the search terms “SARS-CoV-2” or “coronavirus” or “COVID-19” AND “supplement” or “phytonutrient” or “nutraceutical” AND “review.” There were no restrictions on time period, language, or place of publication, and only review articles were included. This yielded 137 review articles after removing duplicates, from which titles and abstracts were reviewed. Sixty-seven articles were then removed for not pertaining to the research question and 25 for not being review articles, leaving 45 articles for full-text review and data extraction.

Our data extraction tool at this step focused on determining which nutraceuticals are most efficacious for the treatment or prevention of COVID-19 and included the name of the nutraceutical considered, the type of studies included in the review (e.g., in vitro, in vivo, animal or human studies), and the evidence for use against COVID-19.

For the purpose of our review, a nutraceutical was considered efficacious if our data extraction tool resulted in two or more reviews in favor of that nutraceutical’s ingestion for COVID-19, either through food or supplement form, and no reviews indicating harm from use. Nutraceuticals for which there was only one review in favor were searched again in PubMed for original articles. If this secondary search yielded two or more original results in its favor, that nutraceutical was also included. This process resulted in the inclusion of the following nutraceuticals for review of the safety of single-nutrient supplements in patients with cancer: vitamin D, vitamin C, zinc, selenium, omega-3 fatty acids, and quercetin (see Supplementary Materials).

At the next step of the process, for each of the identified “anti-COVID-19” nutrients, we conducted a new PubMed search regarding safety for use in patients with cancer. The search was performed using the nutraceutical name (e.g., “vitamin D”) AND “supplement” AND “cancer” AND “survivorship” or “safety” or “recurrence” or “disease progression” or “mortality” or “adverse events.” Additional articles were sourced from a hand-search of
related literature by the included authors. After duplicate removal, this yielded 470 articles in total across all included nutraceuticals for review.

3. Results

Out of 470 articles reviewed, 406 were excluded, leaving a total of 52 independent studies across all included nutraceuticals for data extraction (two of which included data for two nutraceuticals, resulting in a total of 54 records [35,36]). From those 52 studies, we extracted information about the authors, type of study, participants, cancer studied, nutraceutical dosing, and results. The search and selection process is graphically illustrated in Figure 1, and extracted information from the retrieved studies is shown in Tables 1–5.

![Figure 1. Search methodology and article selection process.](image)

3.1. Vitamin D

A total of 177 unique articles were retrieved for vitamin D through our PubMed search. We reviewed titles and abstracts, resulting in 35 for full-text review. After a full-text review, 26 articles remained for data extraction (Table 1).

Of those 26 studies, 23 reported results that indicated benefit, no harm, or null effects of vitamin D supplementation for patients with cancer. Two of the studies reported results with a negative impact for patients with cancer, and one study reported mixed results.

In the studies that found that vitamin D supplements were either beneficial or not harmful for patients with cancer, nine found that supplementation had no effect on a variety of outcomes including symptom management, risk of death, and risk of recurrence [43,51,52,54,57–61].
Table 1. Safety of vitamin D supplements for patients with cancer.

| Study | Type | Participants | Cancer | Dosage | Outcomes | Safety |
|-------|------|--------------|--------|--------|----------|--------|
| Andersen et al., 2019 [37] | Observational | n = 553 patients with breast cancer/survivors (193 from cohort saw naturopathic physicians specializing in oncology, 360 usual care cohort) | Breast cancer | >50% reported taking <1000 IU daily | Users reported ↑ physical function, role-physical function, social function, and role-emotional function on the SF-36 HRQOL 2 assessment subscales at baseline (p < 0.05) | (+) |
| | | Age (mean ± SD) oncology cohort 53 ± 11 y; usual care cohort 55 ± 10 y | All stages | | At 6-month follow-up, users at baseline reported ↑ role-physical function, less pain, better general health, and ↑ vitality and social function (p < 0.05) | |
| | | Female | Therapy: chemotherapy and/or radiation | | Users at 6-month follow-up reported ↑ social function and mental health when assessed at the 12-month follow-up (p < 0.05) | |
| | | BMI not reported | | | | |
| Bjelakovic et al., 2014 [38] | Cochrane review | n = 50,623 | All cancers | Users had ↓ cancer mortality (RR = 0.88, 0.78–0.98, p = 0.02; 44,492 participants; 4 trials) | (+) |
| | | Age (range) 18–107 y | All stages | | | |
| | | Male and female | Therapy not specified | | | |
| | | BMI not reported | Dose titrated to achieve serum levels of 60 ng/mL | | | |
| Campbell et al., 2021 [39] | Intervention | n = 68 | Prostate cancer | Participants with ↑ initial vitamin D levels were twice as likely to have ↓ prostate-specific antigen slope (OR = 2.04, 1.04–4.01, p = 0.04) | (+) |
| | | Age (range) 59–67 y | Stage 1 | | | |
| | | Male | Therapy not specified | | | |
| | | BMI not reported | | | | |
| Chen et al., 2019 [40] | Prospective cohort study | n = 30,899 | All cancers | Users had ↑ risk of cancer mortality (RR = 2.11, 1.18–3.77) | (–) |
| | | Age 20+ y | All stages | | | |
| | | Male and female | Therapy not specified | | | |
| | | n of non-users/users per BMI category, 4301/4401 (<25 kg/m²), 5119/4862 (25–30 kg/m²), 5483/4388 (≥30 kg/m²) | Evaluated use as >10 mg/d from a 30-day questionnaire | | | |
| Chlebowski et al., 2013 [41] | Literature review | n ranged from 200 to >100 participants per study | Breast cancer | Varied based on study | Prospective cohort studies showed no association between ↓ 25(OH)D³ levels and ↓ breast cancer incidence | (+) |
| | | Age not reported | All stages | | | |
| | | Male and female | Therapy: bisphosphonate, chemotherapy, aromatase inhibitor therapy, letrozole, zoledronic, or unspecified | | | |
| | | BMI not reported | | | | |
| Chowdhury et al., 2014 [42] | Systematic review and meta-analysis | n = 849,412 in observational studies | Breast cancer | Varied based on study | Observational studies report associations of ↓ circulating 25(OH)D with ↑ risk of mortality from cancer | (+) |
| | | n = 30,716 in interventional studies | All cancers | | | |
| | | Age not reported | All stages | | | |
| | | Male and female | Therapy not specified | | | |
| | | BMI not reported | | | | |

2 SF-36: Short Form Health Survey

3 25(OH)D: 25-hydroxyvitamin D

4 RCT: Randomized controlled trial
Table 1. Cont.

| Study                     | Type               | Participants                             | Cancer                  | Dosage                                | Outcomes                                                                 | Safety |
|---------------------------|--------------------|------------------------------------------|-------------------------|---------------------------------------|---------------------------------------------------------------------------|--------|
| Cook et al., 2010 [43]    | Meta-analysis      | Total n not reported                     | Ovarian cancer          | Varied based on study                 | About half of the case-control studies reported ↓ mortality with ↑ latitude, solar radiation, or dietary intake or supplementation, and the rest had null associations | (+)    |
|                           |                    | Age not reported                         |                         |                                       | Cohort studies found no risk reduction with ↑ dietary intake or supplementation pre-diagnosis (note: vitamin D intakes were low in all studies) |        |
|                           |                    | Sex not reported                         |                         |                                       |                                                                           |        |
|                           |                    | BMI not reported                         |                         |                                       |                                                                           |        |
|                           |                    |                                         |                         |                                       |                                                                           |        |
| Datta et al., 2012 [44]   | Review             | Total n not reported                     | Prostate cancer         | Varied based on study                 | Clinical trial evidence does not show that supplementation with calcium and vitamin D prevents loss of bone mineral density during androgen deprivation therapy | (+)    |
|                           |                    | Age not reported                         |                         |                                       |                                                                           |        |
|                           |                    | Sex not reported                         |                         |                                       |                                                                           |        |
|                           |                    | BMI not reported                         |                         |                                       |                                                                           |        |
|                           |                    |                                         |                         |                                       |                                                                           |        |
| Du et al., 2017 [45]      | Review             | Total n not reported                     | Gastric cancer          | Varied based on study                 | Inconsistent results on efficacy                                          | (+)    |
|                           |                    | Age not reported                         |                         |                                       |                                                                           |        |
|                           |                    | Sex not reported                         |                         |                                       |                                                                           |        |
|                           |                    | BMI not reported                         |                         |                                       |                                                                           |        |
|                           |                    |                                         |                         |                                       |                                                                           |        |
| Grant et al., 2019 [46]   | Review             | Total n not reported                     | All cancers             | Varied based on study                 | Meta-analysis of 10 RCTs involving 45,197 participants found vitamin D use (variable dose and duration) was associated with 15% ↓ cancer mortality (RR = 0.85, 0.75–0.96) | (+)    |
|                           |                    | Age not reported                         | All stages              |                                       |                                                                           |        |
|                           |                    | Sex not reported                         | All stages              |                                       |                                                                           |        |
|                           |                    | BMI not reported                         | Therapy: androgen deprivation therapy | Varied based on study                 | Vitamin D deficiency may ↑ the risk and mortality of gastric cancer       | (+)    |
|                           |                    |                                         |                         |                                       |                                                                           |        |
| Holm et al., 2014 [48]    | Prospective cohort | n = 1064                                 | Breast cancer           | Not reported                          | Use was associated with ↑ breast cancer mortality (HR = 1.47, 1.07–2.00) | (−)    |
|                           |                    | Age not reported                         | Stage not reported      |                                       |                                                                           |        |
|                           |                    | Female                                   | Therapy: hormone replacement therapy vs. no therapy pre-diagnosis | Varied based on study |                                                                           |        |
|                           |                    | BMI (median) 24.7 kg/m²                   |                         |                                       |                                                                           |        |
|                           |                    |                                         |                         |                                       |                                                                           |        |
| Kanellopoulou et al., 2021 [49] | Meta-analysis | Total n not reported                     | All cancers             | Not reported                          | In breast cancer survivors, use ↓ risk of total mortality (RR = 0.85, 0.72–0.99) | (+)    |
|                           |                    | Age not reported                         | All stages              |                                       |                                                                           |        |
|                           |                    | Sex not reported                         | All stages              |                                       |                                                                           |        |
|                           |                    | BMI not reported                         | Therapy not specified   |                                       |                                                                           |        |
Table 1. Cont.

| Study                     | Type              | Participants                                                                 | Cancer                        | Dosage                        | Outcomes                                                                 | Safety |
|--------------------------|-------------------|------------------------------------------------------------------------------|-------------------------------|-------------------------------|---------------------------------------------------------------------------|--------|
| Khan et al., 2017 [50]   | RCT               | • n = 160<br>• Age (range) 54–69 y<br>• Female<br>• Average group BMI (placebo/supplementation) was 29.6/29.9 kg/m², respectively | Breast cancer<br>• All stages<br>• Therapy: chemotherapy and/or radiation | 30,000 IU vitamin D3 weekly   | • Scores for measures of pain intensity in BPI 5 were better in women randomized to vitamin D compared to placebo<br>• Worsening of aromatase inhibitor-associated musculoskeletal symptoms observed in 71% of subjects randomized to placebo (plus the standard supplement of 60IU of D3/day) vs. 40% of subjects randomized to high dose vitamin D3 plus the standard supplemental dose (p < 0.001)<br>• Six months of oral vitamin D3 at 30,000 IU/week was safe in women starting an aromatase inhibitor for adjuvant treatment of breast cancer and is effective to ↑ serum 25(OH)D levels | (+)    |
| Klapdor et al., 2012 [51]| Prospective cohort<br> | • n = 248 ambulatory patients (n = 103 with pancreatic cancer)<br>• Age not reported<br>• Sex not reported<br>• BMI not reported | Pancreatic cancer<br>• Stage not reported<br>• Therapy: pancreatic enzyme drugs | Vitamin D oral to ↑ serum levels to >30 ng/mL in group II and in the patients of group III in order to reach stable serum 25(OH)D concentrations in the normal range<br>• Doses varied | Oral vitamin D can be supplied without side-effects | (+)    |
| Lewis et al., 2016 [52]  | Prospective cohort<br> | • n = 453<br>• Age (mean) 63.3 y<br>• Male and female<br>• BMI (mean) 28.7 kg/m² | Colorectal cancer<br>• Stage II<br>• Therapy: any | Not reported | No association between vitamin D use and risk of recurrence or mortality<br>• Beneficial association between use and functional assessment in colorectal cancer subscale of the FACT-C 6 (p = 0.04) | (+)    |
| Madden et al., 2018 [53] | Longitudinal cohort<br> | • n = 5417<br>• Age at diagnosis (range) 50–80 y<br>• Female<br>• BMI not reported | Breast cancer<br>• Stage I–III<br>• Therapy: any | Categories of no use, 1–400 IU/day, and >400 IU/day | 20% ↓ in breast cancer-specific mortality in de novo vitamin D users vs. non-users (HR = 0.80, p = 0.048)<br>• 49% ↓ breast cancer-specific mortality if vitamin D initiated within 6 months of breast cancer diagnosis (HR = 0.51, p < 0.001) | (+)    |
| Martinez et al., 2012 [54]| Review            | • Total n not reported<br>• Age not reported<br>• Sex not reported<br>• BMI not reported | All cancers<br>• Stage not reported<br>• Therapy not specified | Not reported | One RCT showed no effect of use on cancer mortality<br>• One RCT showed no effect of use in breast or colorectal cancer incidence with vitamin D plus calcium<br>• One RCT showed ↓ in total cancer incidence with vitamin D plus calcium vs. placebo | (+)    |
| Study                        | Type                        | Participants                                                                 | Cancer                                      | Dosage                                                                 | Outcomes                                                                 | Safety                      |
|-----------------------------|-----------------------------|------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------|
| Morita et al., 2021 [55]    | Post-hoc analysis of RCT    | • n = 396                                                                     | Digestive tract                             | 200 IU/day vs. placebo, until relapse or death                         | In lowest PD-L1 \(^7\) quintile, vitamin D upregulated serum PD-L1 levels (\(p = 0.0008\)); no change with placebo | (+/-)                       |
|                             |                             | • Age (median) 66 y                                                           | Stage I–III                                  |                                                                        | In the highest quintile, vitamin D downregulated serum PD-L1 levels (\(p = 0.0011\)); no change with placebo |                             |
|                             |                             | • Male and female                                                            | Therapy: post-curative surgery with complete tumor resection |                                                                        | A significant effect of vitamin D on death, compared with placebo, only in the highest PD-L1 quintile (HR = 0.34, 0.12–0.92); not observed in other quintiles |                             |
|                             |                             | • BMI (median) 21.9 kg/m\(^2\)                                               |                                             |                                                                        | Significant effect of vitamin D on death or relapse, compared with placebo, only in the highest PD-L1 quintile (HR = 0.37, 0.15–0.89) |                             |
| Mulpur et al., 2015 [56]    | Cohort                      | • n = 470                                                                     | Glioblastoma                                | Not reported                                                           | Vitamin D use associated with ↓ age-adjusted mortality (HR = 0.68, \(p = 0.019\)) and after multivariate adjustment (HR = 0.72, \(p = 0.043\)) | (+)                         |
|                             |                             | • Age (median) 59 y                                                           | High grade                                  |                                                                        | Results for vitamin D attenuated when the reference category confined to non-alternative medicine users in a multivariate model |                             |
|                             |                             | • Male and female                                                            | Theraoy: standard of care treatment involving surgery, chemotherapy, and radiation therapy |                                                                        |                                                          |                             |
|                             |                             | • BMI not reported                                                           |                                             |                                                                        |                                                          |                             |
| Poole et al., 2013 [35]     | Cohort                      | • n = 12,019                                                                  | Breast cancer                               | Not reported                                                           | Vitamin D use was associated with ↓ risk of recurrence in ER\(^+\) tumors (HR = 1.25) | (+)                         |
|                             |                             | • Age (mean) 56.8 y                                                          | Excluded in situ or stage IV                |                                                                        | Stratified by joint ER/PR status, vitamin D was only associated with ↓ risk of recurrence in ER\(^+\)/PR\(^+\) and ER\(^+\)/PR\(^-\) tumors, but not ER\(^-\)/PR\(^+\) or ER\(^-\)/PR\(^-\) tumors (\(p = 0.002\) for interaction) |                             |
|                             |                             | • Female                                                                     | Therapy: varied—chemotherapy, radiation, or hormone therapy present in cohort |                                                                        |                                                          |                             |
|                             |                             | • Frequency of BMI < 25 kg/m\(^2\), 25–30 kg/m\(^2\), and ≥30 kg/m\(^2\) was roughly 50%, 30%, and 20%, respectively |                                             |                                                                        |                                                          |                             |
| Saquib et al., 2011 [57]    | Cohort derived from RCT     | • n = 3080                                                                    | Breast cancer                               | 6 \(\mu\)g/day total intake of vitamin D in those who took supplements | No significant findings related to all-cause mortality                  | (+)                         |
|                             |                             | • Age (mean) 53 y                                                             | Operable invasive stage I (≥1 cm)            |                                                                        |                                                          |                             |
|                             |                             | • Female                                                                     | II, or IIIA                                  |                                                                        |                                                          |                             |
|                             |                             | • 24% of users and 36% of non-users had obesity                              | Therapy: none (study done in survivors)     |                                                                        |                                                          |                             |
| Sarre et al., 2016 [58]     | Cohort from men participating in the third round of the FinRSPC \(^1\) randomized screening study | • n = 12,740                                                                  | Prostate cancer                             | Not reported                                                           | Vitamin D use had no association with prostate cancer incidence, high-grade/metastatic cancers, or death | (+)                         |
|                             |                             | • Ages: 63, 67, or 71 y                                                      | Stage not reported                           |                                                                        |                                                          |                             |
|                             |                             | • Males                                                                      | Therapy not specified                        |                                                                        |                                                          |                             |
|                             |                             | • BMI not reported                                                           |                                             |                                                                        |                                                          |                             |
| Wang et al., 2016 [59]      | Longitudinal observational  | • n = 300                                                                     | Esophageal cancer                           | 200–400 IU/day for 1 year                                             | Associations between use and QOL \(^1\), including global health, physical functioning, social functioning, fatigue, and appetite loss measured by QLQ-C30 \(^2\) | (+)                         |
|                             |                             | • Age of users and non-users (means) 62 and 65 y, respectively               | Roughly 65% stage 0/1/I1, 35% stage III/IV, 44% with lymph node involvement |                                                                        | Users more likely to have improved disease-free survival (\(p = 0.030\)) |                             |
|                             |                             | • Predominately male                                                         | Therapy: esophagectomy and some with postoperative chemotherapy and/or radiotherapy |                                                                        | No association of use with overall survival                          |                             |
|                             |                             | • BMI (mean) 21 kg/m\(^2\)                                                   |                                             |                                                                        |                                                          |                             |

**Table 1. Cont.**
Table 1. Cont.

| Study                        | Type                          | Participants                                                                 | Cancer                                                                                   | Dosage                                                                 | Outcomes                                                                 | Safety       |
|------------------------------|-------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------|
| Zhang et al., 2019 [60]      | Meta-analysis of RCTs         | ● \(n = 77,653\) from 9 studies                                             | ● All cancers                                                                             | ● Varied across 9 studies                                               | ● No significant effect on cancer incidence or mortality                  | (+)          |
|                              |                               | ● Age (range) \(20-84\) y                                                   | ● Staging not reported                                                                   |                                                                        |                                                                           |              |
|                              |                               | ● Male and female                                                           | ● Therapy not specified                                                                  |                                                                        |                                                                           |              |
|                              |                               | ● BMI not reported                                                          |                                           |                                                                        |                                                                           |              |
|                              |                               |                                                                              |                                           |                                                                        |                                                                           |              |
| Zirpoli et al., 2017 [61]    | Cohort                        | ● \(n = 922\)                                                               | ● Breast cancer                                                                          | ● Not reported                                                          | ● No improvement in peripheral neuropathy Fact-NTX \(^{13}\) or CTCAE \(^{14}\) scores | (+)          |
|                              |                               | ● Age not reported                                                          | ● Stage I-III breast cancer (node-positive (pN1-3))                                      |                                                                        |                                                                           |              |
|                              |                               | ● Female                                                                    | ● Any primary tumor \(\geq 2\) cm, or any tumor \(\geq 1\) cm if estrogen receptor      |                                                                        |                                                                           |              |
|                              |                               | ● BMI not reported                                                          | negative/progesterone receptor negative or hormone receptor positive with 21-gene     |                                                                        |                                                                           |              |
|                              |                               |                                                                              | recurrence score \(\geq 26\)                                                           |                                                                        |                                                                           |              |
|                              |                               |                                                                              | ● Therapy: paclitaxel (1/week for 12 weeks or every other week)                          |                                                                        |                                                                           |              |

Abbreviations used: \(^{1}\) Body Mass Index, \(^{2}\) Short Form Health-Related Quality of Life, \(^{3}\) 25-hydroxy vitamin D, \(^{4}\) Randomized Controlled Trial, \(^{5}\) Brief Pain Index, \(^{6}\) Functional Assessment of Cancer Therapy—Colorectal, \(^{7}\) Programed death ligand \(^{1}\), \(^{8}\) Estrogen Receptor, \(^{9}\) Progesterone Receptor, \(^{10}\) Finnish Randomized Study for Screening of Prostate Cancer, \(^{11}\) Quality of Life, \(^{12}\) Quality of Life Questionnaire-Core Questionnaire, \(^{13}\) Functional Assessment of Cancer Therapy-Neurotoxicity, \(^{14}\) Common Terminology Criteria for Adverse Events. The last column indicates the overall direction of the effects of vitamin D supplementation on safety: (+) no risks to health; (−) some risks to health outcomes; (+/−) mixed risk profile. Relative risks (RR) and odds/hazard ratios (OR/HR) are shown as means with 95% confidence intervals.
Table 2. Safety of vitamin C supplements for patients with cancer.

| Study                      | Type                    | Participants                                                                 | Cancer                          | Dosage                                                                 | Outcomes                                                                 | Safety |
|----------------------------|-------------------------|------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|--------|
| Ambrosone et al., 2020 [34]| Correlative analysis from SWOG S0221 | • $n = 1134$
• Age (mean) progression free 50.9 y
• Age (mean) with progression 52.8 y
• Female
• BMI $^1$ (mean) progression free 29.1 kg/m$^2$
• BMI (mean) with progression 30.1 kg/m$^2$
| Breast cancer
• Stage not available, mostly node-negative
• Randomized to treatment of cyclophosphamide, doxorubicin, and paclitaxel | • Not reported                                                                 | • No association with use of vitamin C before and during treatment and recurrence (HR = 1.36, 0.87–2.13)
• No association with vitamin C and overall survival | (+) |
| Bjelakovic et al., 2008 [62]| Systematic review       | • $n$ not reported
• Age not reported
• Male and female
• BMI not reported | Gastrointestinal cancer
• Stage not reported
• Therapy not specified | Dose ranged 120–2000 mg/day depending on the trial | Vitamin C supplement use
(RR = 0.97, 0.77–1.23) did not influence mortality
• Combination vitamin C with beta-carotene, vitamin E, and selenium did not influence mortality compared to placebo | (+) |
| Greenlee et al., 2012 [63]| Cohort                  | • $n = 2264$
• Age (range) 18–79 y
• Female
• BMI not reported
• Majority had BMI < 25 kg/m$^2$
| Breast cancer
• Stage I–IIIA
• Therapy completed | Categories of no use, occasional use ($<$1–5 days/week), and frequent use (6–7 days/week)
• No details on dose | Frequent use of vitamin C associated with ↓ risk of breast cancer recurrence (HR = 0.79, 0.55–0.97) | (+) |
| Harris et al., 2013 [64]| Cohort                  | • $n = 3405$
• Age (mean) at dx $^2 = 65$ y
• Female
• Mean BMI = 25 kg/m$^2$
| Breast cancer
• All stages
• All therapies | $\approx$1000 mg/day
• Therapy completed | No association between vitamin C supplement use and breast cancer-specific mortality (HR = 1.06, 0.52–2.17) | (+) |
| Harris et al., 2014 [65]| Meta-analysis           | • $n$ not reported
• Age not reported
• Female
• BMI not reported | Breast cancer
• Stage not reported
• All therapies | Various
• Therapy completed | Post-diagnosis usage reduced breast cancer-specific mortality (RR = 0.85, 0.74–0.99) | (+) |
| Jacobs et al., 2002 [66]| Cohort                  | • $n = 942,993$
• Age $^2$ y
• Male and female
• BMI not reported | Stomach cancer
• Stage not reported
• Therapy not specified | Not reported | Regular vitamin C use tended to ↓ risk of stomach cancer mortality
(RR = 0.83, 0.67–1.01)
• ↓ risk only in participants using vitamin C for a relatively short duration of time (RR = 0.68, 0.53–0.91 for $<$10 years use; RR = 1.00, 0.73–1.38 for $\geq$10 years use) | (+) |
| Jacobs et al., 2002 [67]| Cohort                  | • $n = 991,552$
• Age not reported
• Male and female
• BMI not reported | Bladder cancer
• Stage not reported
• All therapies | Not reported | Regular vitamin C supplement use (≥15 times per month) not associated with bladder cancer mortality | (+) |
| Kanellopoulo et al., 2020 [49]| Meta-analysis          | • $n$ not reported
• Age $^3$ y
• Male and female
• BMI not reported | All cancers
• Stage 0–IV
• All therapies | Not reported | In breast cancer survivors, vitamin C supplement use associated with ↓ total mortality
• Vitamin C supplement use associated with ↓ breast cancer recurrence (RR = 0.76) | (+) |
| Study                           | Type     | Participants | Cancer                                                                 | Dosage  | Outcomes                                                                 | Safety |
|--------------------------------|----------|--------------|-------------------------------------------------------------------------|---------|---------------------------------------------------------------------------|--------|
| Lin et al., 2009 [68]          | RCT      | n = 7627     | Any cancer                                                             | 500 mg/day | No effects of use of any antioxidant on cancer incidence. Vitamin C vs. placebo, no difference in mortality | (+)    |
|                                |          | Age (mean) 60.4 y Female BMI (mean) 30 kg/m² in Vitamin C group | No dx at baseline Therapy: none                                       |         |                                                                           |        |
| Messerer et al., 2008 [69]     | Cohort   | n = 38,994   | All cancers                                                            | Estimated 1000 mg/day | No association between use of any dietary supplementation and all-cause mortality, cancer, or CVD mortality | (+)    |
|                                |          | Age (range) 45–79 y Male BMI not reported | No cancer at baseline Therapy: none                                    |         |                                                                           |        |
| Nechuta et al., 2011 [70]      | Cohort   | n = 4877     | Breast cancer                                                          | Majority consumed < 400 mg/day supplement | Use of vitamin C for >3 months had a 44% ↓ in risk of mortality and 38% ↓ in risk of recurrence | (+)    |
|                                |          | Age (range) 20–75 y Female BMI not reported | Stage I–IV All therapies                                               |         |                                                                           |        |
| Pocobelli et al., 2009 [71]    | Cohort   | n = 77,719   | All cancers                                                            | Varied   | Vitamin C use associated with ↓ risk of cancer mortality, but no dose-response trend | (+)    |
|                                |          | Age 50–76 y Male and female BMI not reported | Breast cancer Excluded in situ or stage IV Therapy: varied—chemotherapy, radiation, or hormone therapy |         |                                                                           |        |
| Poole et al., 2013 [35]        | Cohort   | n = 12,019   | Breast cancer                                                          | Not reported | Vitamin C use associated with ↓ risk of death (RR = 0.81) Use of antioxidants supplements (multivitamins, vitamin C or E) not associated with recurrence | (+)    |
|                                |          | Age (mean) 56.8 y Female | Excluded in situ or stage IV Therapy: varied—chemotherapy, radiation, or hormone therapy |         |                                                                           |        |
|                                |          | Frequency of BMI was roughly 50% < 25 kg/m², 30% 25–29.9 kg/m², 20% above 30 kg/m² | Therapy: varied—chemotherapy, radiation, or hormone therapy |         |                                                                           |        |
|                                |          | | | | | |
| Zirpoli et al., 2017 [61]      | Cohort   | n = 922      | Breast cancer                                                          | Not reported | Use of vitamin C, folic acid, calcium, iron, or fish oil before diagnosis was not associated with CTCAE grade 3 or 4 neurotoxicity | (+)    |
|                                |          | Age not reported Female BMI not reported | Stage I–III (node-positive pN1–3) Any primary tumor ≥ 2 cm, or any tumor ≥ 1 cm estrogen receptor negative/progesterone receptor negative or hormone receptor positive with 21-gene recurrence score ≥ 26 Therapy—Paclitaxel (1x/week for 12 weeks or every other week) |         |                                                                           |        |

Abbreviations used: 1 Body Mass Index, 2 diagnosis, 3 Randomized Control Trial, 4 Cardiovascular disease, 5 Common Terminology Criteria for Adverse Events. The last column indicates the overall direction of the effects of vitamin C supplementation on safety: (+) no risks to health; (−) some risks to health outcomes; (+/−) mixed risk profile. Relative risks (RR) and odds/hazard ratios (OR/HR) are shown as means with 95% confidence intervals.
Table 3. Safety of selenium supplements for patients with cancer.

| Study                  | Type                          | Participants                                                                 | Cancer                                    | Dosage                                                                 | Outcomes                                                                 | Safety                  |
|------------------------|-------------------------------|------------------------------------------------------------------------------|-------------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------|
| Bjelakovic et al., 2008 [62] | Systematic review of RCTs ¹  | • n = 211,818 participants total in 20 RCTs  
• Age (mean) 56.5 y (range 15–84 y)  
• Male (59%) and female  
• BMI ² not reported | Gastrointestinal cancer  
• All stages  
• Therapy not specified | • Not reported | Selenium use (singly or with other antioxidants) significantly ↓ mortality (RR = 0.90, 0.83–0.98), effect attenuated when high-risk trials excluded (+) |
| Jenkins et al., 2020 [72] | Systematic review/meta-analysis of RCTs | • n not reported  
• Age not reported  
• Male and female  
• BMI not reported | All cancers  
• All stages (and mortality)  
• Therapy not specified | • Not reported | Selenium supplement use, singly or with other antioxidants, was not associated with cancer incidence or cancer mortality (+) |
| Jiang L et al., 2010 [73] | Meta-analysis of RCTs | • n = 165,056 participants across 9 RCTs  
• Age not reported  
• Male  
• BMI not reported | Prostate cancer  
• All stages  
• Therapy not specified | • Not reported | Mortality among patients with prostate cancer did not significantly differ by selenium supplementation (RR = 2.98, 0.12–73.2)  
Incidence/mortality of prostate cancer did not ↓ with selenium supplement intake (+) |
| Kenfield et al., 2015 [74] | Prospective cohort study | • n = 4459  
• Age (mean) 68.9 +/? 7.2 y at diagnosis  
• Male  
• BMI (mean) 25.8 kg/m² | Prostate cancer  
• Not metastatic at diagnosis  
• Therapy: radical prostatectomy, EBRT ³ or brachytherapy, hormones, watchful waiting, or other | • 1–24 µg/day,  
25–139 µg/day or  
140+ µg/day of selenium supplement | No ↑ risk of prostate cancer mortality in 1–24 µg/day and 25–139 µg/day selenium supplementation  
↑ risk of prostate cancer mortality in 140+ µg/day selenium supplementation vs. those not taking supplement (+/-) |
| Muecke R et al., 2010 [75] | RCT | • n = 81  
• Age (mean) 64.3 ± 10.1 y; (range) 31–80  
• Female  
• BMI not reported | Cervical and uterine cancer  
• All stages  
• Therapy: radiation therapy | | Radiation therapy days = 500 µg of selenium  
Other days = 300 µg of selenium  
17 mg of sodium selenite given cumulatively over average treatment period of 38 days | In 10 years of follow-up, no difference in disease-free survival between selenium group and control (p = 0.65)  
No difference in 10-year overall survival rate in selenium group vs. control (p = 0.09) (+) |
| Samuels et al., 2014 [76] | Review | • Total n not reported  
• Age not reported  
• Sex not reported  
• BMI not reported | Breast cancer  
• All stages  
• Therapy in 1RCT: standard combined decongestion therapy | • 1 RCT—  
1st week = 1000 µg/d,  
2nd week = 300 µg/d,  
final weeks = 100 µg/d for 3 total months  
1 cohort = 350 µg/m² daily for 4–6 weeks | 1 RCT: 179 post-mastectomy patients with secondary lymphoedema. Selenium supplement use ↓ in edema volumes  
incidence of skin infections vs. controls  
1 cohort: 48 patients with post-radiation lymphoedema (12 patients also had breast cancer). 83.3% of those with cancer had ↓ in edema with supplementation (+) |

Abbreviations used: ¹ Randomized Controlled Trial, ² Body Mass Index, ³ External Beam Radiation Therapy. The last column indicates the overall direction of the effects of selenium supplementation on safety: (+) no risks to health; (−) some risks to health outcomes; (+/−) mixed risk profile. Relative risks (RR) and odds/hazard ratios (OR/HR) are shown as means with 95% confidence intervals.
Table 4. Safety of omega-3 fatty acid supplements for patients with cancer.

| Study                        | Type                  | Participants                                      | Cancer                          | Dosage         | Outcomes                                                                 | Safety |
|------------------------------|-----------------------|---------------------------------------------------|---------------------------------|----------------|--------------------------------------------------------------------------|--------|
| Campbell et al., 2021 [39]   | Intervention          | n = 68; Age (range) 59.3–66.9 y; Male; BMI not reported | Prostate cancer; Stage 1 (very low or low risk); Therapy not specified | 720 mg (3/day) | Relationship between prostate-specific antigen slope and initial total omega-3 levels were not statistically significant (r = –0.1, p = 0.95), final omega-3 levels (r = 0.16, p = 0.531), and final omega-6:3 ratio (r = –0.28, p = 0.282) | (+)    |
| Klassen et al., 2020 [77]    | Review article        | n = 140 participants across studies; Male and female; BMI not reported | Breast and gastrointestinal cancers; All stages; Therapy: chemotherapy or otherwise not specified | Varied across studies | All study results support safety/tolerability of omega-3 supplement during chemotherapy | (+)    |
| Miyata et al., 2017 [78]     | RCT 2                 | n = 61 patients; Age (range) 56.1–72.7 y; 52 male, 9 female; BMI Omega-3 group (mean) 21.8 ±/− 10 kg/m², placebo group (mean) 20.8 ±/− 7.1 kg/m² | Esophageal cancer; All stages; Therapy: neoadjuvant chemotherapy | 900 mg/day omega-3 in intervention group and 250 mg/day in comparison group | Both groups had enteral nutrition supplement provided 3 days before initiation of chemotherapy to day 12 of chemotherapy; No difference in incidence of grade 3/4 neutropenia between both groups (77.4% in intervention vs. 83.3% in comparison p = 0.561) or frequency (90.3% in intervention vs. 86% in comparison, p = 0.363) | (+)    |
| Mulpur et al., 2015 [56]     | Longitudinal cohort   | n = 106; Age (range) 18–84 y; Male and female; BMI not reported | Glioblastoma; All stages; Therapy: surgery, chemotherapy, radiation | Not reported | No effect of omega-3 supplementation on mortality | (+)    |
| Shen et al., 2018 [79]       | Exploratory analysis of RCT | n = 249; Age (median) 59 y; 56% = BMI < 30; 44% = BMI ≥ 30 | Breast cancer; Stages I-III; Aromatase-inhibitor therapy | 3.3 g/day (560 mg EPA ³ plus DHA ⁴ acid in a 40:20 ratio) omega-3 in intervention group and placebo (soybean-corn oil blend) in comparison group for 24 weeks | Omega-3 supplement use associated with j; BPI ⁵ worst pain scores vs. placebo (4.36 vs. 5.70, p = 0.02) in patients with obesity; No difference in scores between treatment arms (5.27 vs. 4.58, p = 0.28; p = 0.05) in patients who weren’t obese | (+)    |
| Sorensen et al., 2020 [80]   | RCT                   | n = 148; Age (mean) 68.3 ±/− 11.3 y; Male and female; BMI not reported | Colorectal cancer; All stages; Therapy: surgery | Intervention group, 2.0 g EPA and 1.0 g DHA per day; No EPA/DHA for control group | No difference in 5-year survival for intervention group vs. control (p = 0.193); Adjusted for age/disease stage/therapy, omega-3 supplement associated with †; mortality (HR = 1.73, 1.06–2.83; p = 0.029) | (−)    |
Table 4. Cont.

| Study                  | Type           | Participants                          | Cancer            | Dosage | Outcomes                                                                 | Safety                                                                 |
|------------------------|----------------|---------------------------------------|-------------------|--------|--------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Vernieri et al., 2018  | Review         | Total \( n \) not reported            | All cancers       | Not reported | Omega-3 supplement was tolerable with antitumor activity in 2 prospective trials for patients with advanced lung and breast cancer | (+/−)                                                                   |
|                        |                | Age not reported                       | All stages        |         | Preclinical study reported that the 16:4 (\( n \)-3) omega-3 in commercial fish oils impedes tumor-directed cytotoxicity of platinum compounds. Warns against indiscriminate fish oil supplementation | (+/−)                                                                   |
|                        |                | Male and female                        | Therapy not specified |        |                                                                           |                                                                         |
|                        |                | BMI not reported                       |                    |        |                                                                           |                                                                         |
|                        |                |                                       |                   |        |                                                                           |                                                                         |

Abbreviations used: 1 Body Mass Index, 2 Randomized Controlled Trial, 3 Eicosapentanoic acid, 4 Docosahaxaenoic acid, 5 Brief Pain Inventory. The last column indicates the overall direction of the effects of Omega-3 supplementation on safety: (+) no risks to health; (−) some risks to health outcomes; (+/−) mixed risk profile. Relative risks (RR) and odds/hazard ratios (OR/HR) are shown as means with 95% confidence intervals.

Table 5. Safety of zinc supplements for patients with cancer.

| Study                  | Type           | Participants                          | Cancer            | Dosage | Outcomes                                                                 | Safety                                                                 |
|------------------------|----------------|---------------------------------------|-------------------|--------|--------------------------------------------------------------------------|-------------------------------------------------------------------------|
| De Sousa Melo et al., 2021 | Narrative review | \( n \) not reported                   | Head and neck cancer | Varied | Zinc sulfate supplementation ↓ severity of mucositis, delayed its onset | (+/−)                                                                   |
|                        |                | Age not indicated                      | All stages        |        | 25 mg/day ↓ incidence and duration of oral mucositis                    |                                                                         |
|                        |                | Male and female                        | Therapy: various  |        | May induce nausea and vomiting, should not be taken on empty stomach    |                                                                         |
|                        |                | BMI 1 not reported                     |                   |        |                                                                           |                                                                         |

Abbreviations used: 1 Body Mass Index. The last column indicates the overall direction of the effects of Zinc supplementation on safety: (+) no risks to health; (−) some risks to health outcomes; (+/−) mixed risk profile. Relative risks (RR) and odds/hazard ratios (OR/HR) are shown as means with 95% confidence intervals.
Three of the studies found that vitamin D was associated with better quality-of-life outcomes, including better scores on the cancer quality-of-life questionnaire (QLQ-C30) for physical functioning, social functioning, fatigue, and appetite, and better scores on the colorectal cancer subscale of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) tool [37,52,59]. Beyond quality-of-life measures, four studies reported a decrease in cancer mortality in those who took vitamin D supplements, and two showed a decrease in overall mortality [38,43,46,49,53,56]. One study found a lower risk of breast cancer recurrence in those who were supplemented with vitamin D post-diagnosis, but only among estrogen receptor (ER)-positive tumors and not among ER-negative tumors (HR = 0.64, 95% CI: 0.47–0.87 and HR = 1.25, 95% CI: 0.78–1.98; respectively) [35].

In the two studies that found vitamin D supplementation was harmful in patients with cancer, one found a positive association between vitamin D supplement use above 10 µg/day and cancer mortality (RR = 2.11, 95% CI: 1.18–3.77) [40], and the other found that vitamin D supplementation increased the risk of breast cancer mortality (HR = 1.47, 95% CI: 1.07–2.00) [48].

One RCT found mixed results for vitamin D supplementation with 200 IU/day in patients with digestive-tract cancer, post-curative surgery [55]. The study found that the effect of supplementation depended on the levels of serum Programmed Death Ligand 1 (PD-L1), a regulatory molecule expressed in T cells with immunosuppressive function [55]. Since PD-L1 is associated with a poorer cancer prognosis in various types of cancer (gastric cancer, small cell lung cancer, pancreatic cancer, breast cancer) [83–86], for those patients in the lowest PD-L1 concentration quintile, vitamin D supplementation seemed to have a detrimental effect by upregulating serum PD-L1 levels; however, for those in the highest quintile, vitamin D was beneficial and downregulated serum PD-L1 levels [55,87].

3.2. Vitamin C

A total of 190 unique articles were retrieved for vitamin C through our PubMed search. We reviewed titles and abstracts, resulting in 35 for full-text review. After a full-text review, 14 articles remained for data extraction (Table 2).

Of those 14 studies, all provided results in the direction of benefit, no harm, or null effects of vitamin C supplementation in patients with cancer. Six of the fourteen studies found no association between the use of vitamin C supplements and adverse cancer-related events, including recurrence, survival, overall mortality, and cancer-specific mortality [34,62,64,67–69]. Additionally, a study on chemotherapy-induced peripheral neuropathy found no significant effect of pre-treatment vitamin C supplementation on neurotoxicity [61]. Three studies found that vitamin C intake was associated with decreased overall mortality, three found a decreased risk of cancer-specific mortality, and three found a decreased risk of recurrence [35,63,65,66,70,71]. None of the studies reported an increased risk to health from the use of vitamin C supplements.

3.3. Selenium

A total of 45 unique articles were retrieved for selenium through our PubMed search. We reviewed titles and abstracts, resulting in 28 for full-text review. After a full-text review, six articles remained for data extraction (Table 3).

Five of these six papers showed no harmful effects of selenium supplementation in patients with cancer and included two meta-analyses [72,73], two reviews [62,76], and one RCT [75]. Three articles did not find a beneficial effect on the incidence or progression of gastrointestinal cancer [62], prostate cancer [73], or cervical and uterine cancer [75], but found selenium supplementation was not otherwise harmful. Beneficial effects were highlighted in a review that addressed an association between selenium supplementation and decreased edema volumes and incidence of skin infection in patients with breast cancer in an RCT of 179 post-mastectomy patients with secondary lymphedema, as well as decreased edema volumes in 10 out of 12 patients with breast cancer included in a 48-participant cohort study [76].
A meta-analysis of RCTs by Jenkins et al. concluded that selenium taken independently (i.e., not as a multivitamin or mixed with other supplements) was not associated with cancer mortality [72]. However, a prospective cohort study within the review found that high-dose selenium supplementation (≥140 µg/day) may be associated with a greater risk of prostate cancer mortality [72].

3.4. Omega-3 Fatty Acids

A total of 21 unique articles were retrieved for omega-3 fatty acids through our search. We reviewed titles and abstracts, resulting in 17 for full-text review. After a full-text review, seven articles remained for data extraction (Table 4).

In five of these seven studies, there were no adverse effects of supplementation. One study found that supplementation with omega-3 fatty acids decreased aromatase-inhibitor-related pain in patients with breast cancer and obesity [79]. Additionally, omega-3 supplementation showed promising antitumor activity in two prospective trials of patients with advanced lung and breast cancer, as reviewed by Vernieri et al. [81]. The same review, however, highlighted a pre-clinical study that reported that the 16:4 omega-3 (hexadeca-4,7,10,13-tetraenoic) fatty acid supplement, commonly found in commercial fish oils, may be unsafe for patients with cancer as it can hinder tumor-directed cytotoxicity of platinum compounds used in cancer treatments [81].

Furthermore, an RCT pointed towards an increased mortality rate 5 years after patients with colorectal cancer (from a country with traditionally high fish intake) took omega-3 supplements in the 7 days before and after colorectal resection surgery [80].

3.5. Zinc

A total of 25 unique articles were retrieved for zinc through our PubMed search. We reviewed titles and abstracts, resulting in 11 for full-text review. After a full-text review, only one article remained for data extraction (Table 5).

The study found that zinc supplementation reduced the duration and severity of oral mucositis in patients with head and neck cancer but sometimes caused gastrointestinal distress, which suggests that zinc supplements should not be taken on an empty stomach [88].

3.6. Quercetin

A total of 12 unique articles were retrieved for quercetin through our PubMed search. We reviewed titles and abstracts, resulting in five for full-text review. After a full-text review, one was removed for being conducted in animals, and the remaining four were review articles that did not include human studies; therefore, no articles qualified for further consideration.

4. Discussion

This narrative review aimed to synthesize the currently available literature regarding the safety of the most efficacious “anti-COVID-19” nutraceuticals for patients with cancer. Our findings reveal heterogeneous results, with safety largely depending on the type of nutraceutical or supplement consumed, the dose consumed, and the type of cancer studied. Across nutraceuticals, our results were heavily based on observational studies. Taking the potential risk of confounding into consideration, clear conclusions could not be drawn, further emphasizing the need for caution from healthcare providers.

Vitamin D may decrease CRP, which has been implicated in the cytokine storm seen in severe cases of COVID-19 infection [18]. We identified an overwhelming majority of studies with results that point in favor of vitamin D use in patients with cancer, with positive effects seen in quality-of-life measures, mortality, recurrence, and pain indexes. However, the mechanism between vitamin D and these positive cancer-related outcomes was not always well characterized. Anderson et al. documented improved quality-of-life measures in an observational cohort of patients with breast cancer, but ultimately noted
that it was unclear whether the supplement itself was responsible or whether participants who took vitamin D were in general more optimistic or more likely to take other actions towards improving their overall health and mood [37]. Similarly, Bjelakovic et al. reported decreased cancer mortality from vitamin D3 supplementation (RR = 0.88, 95% CI: 0.78–0.98) but noted the lack of RCTs made it hard to draw robust conclusions [38].

Only two studies point to an increased risk of vitamin D intake in patients with cancer; one noted this was observed only among those who were not deficient in vitamin D [40], and the other noted that the association of vitamin D supplementation with higher breast cancer mortality needed further exploration, as there was no clear mechanism behind this observation [48]. Given that the majority of evidence is in support of vitamin D use, oncologists can likely safely allow their patients to continue supplementation at typically recommended doses (600 IU/day).

Vitamin C, similar to vitamin D, may contribute to a decrease in the pro-inflammatory cytokines, which are a hallmark of severe COVID-19 infection [18]. The evidence for vitamin C also strongly points in the direction of supplementation being safe, or perhaps even beneficial, for patients with cancer. In fact, none of the included articles found an indication of harm. Given that there has been concern that the use of antioxidants, including vitamin C, may negatively impact the effect of chemotherapeutic agents, these results are encouraging [70]. Nevertheless, we urge caution as the studies are, by and large, observational in nature, which stresses the need for additional clinical trials [49]. At the present state of knowledge, supplementation with vitamin C at typically recommended doses (75–90 mg/day) is likely not harmful and could conceivably confer benefit.

Selenium may reduce the severity of COVID-19 infection by impeding viral entry into the cytoplasm and has promising results in patients with cancer [89]. All but one out of six studies addressing selenium supplementation demonstrated no adverse effects in patients with cancer. However, the type of cancer (i.e., prostate, uterine, cervical, gastrointestinal) and outcome of interest varied greatly across studies. One prospective cohort study in patients with prostate cancer noted that selenium supplementation might be associated with a higher risk of mortality if intake is high (≥140 µg/day) [72]. Given these results, it is likely that selenium use is safe for patients with cancer, though high-dose supplementation should be avoided (typically recommended doses: 40–70 mg/day).

Omega-3 fatty acids may play a role in decreasing the severity of COVID-19 infection by inhibiting cellular viral entry, suppressing the production of pro-inflammatory cytokines, and increasing the phagocytic capacity of the innate immune system [20]. Out of seven identified articles for omega-3 fatty acids, five found their use to be safe, though estimates of efficacy varied [39,77]. The seven articles addressed safety in a variety of different cancers, including skin cancer, prostate cancer, gastrointestinal cancer, breast cancer, esophageal cancer, glioblastoma, and colorectal cancer. Two studies evaluated the long-term effects of supplementation with omega-3 fatty acids. The first, a longitudinal cohort study, did not find an association between mortality and supplementation in glioblastoma patients [56]. In contrast, the other, an RCT, pointed towards an increased mortality rate after five years of intake in patients with colorectal cancer who supplemented one week before and one week after colorectal resection surgery [80]. Additionally, one review specifically warned against the indiscriminate use of fish oil supplements, which may be unsafe for patients with cancer if they contain hexadeca-4,7,10,13-tetraenoic acid; this omega-3 fatty acid can dampen the tumor-directed cytotoxicity of platinum compounds used to treat some cancers [81]. Based on this evidence, caution should be used as far as omega-3 fatty acid supplements are concerned. At the very least, scrutiny of the exact fatty acid composition of the supplement together with frequent patient monitoring is warranted.

For zinc, which may counteract inflammation associated with tumor necrosis factor-α in COVID-19 infection [90], results did not universally show harm-free supplementation. Although one study indicated a reduced incidence of oral mucositis with supplementation in patients with head and neck cancer, the same study also cited potential gastrointestinal distress at the same dosage [88]. Given the lack of a sufficiently large body of evidence...
on this nutraceutical, with only one study being relevant, it is hard to draw any conclusions. That said, at present, it is probably prudent to advise patients with cancer against supplementation with zinc.

While this review thoroughly and systematically assessed the literature regarding the safety of these supplements for patients with cancer, our conclusions are not without limitations. The heterogeneity of results may in part be due to our inclusion of all stages and types of cancer, as well as our inclusion of all treatment types and clinical settings. It is possible that a narrower scope would have revealed more homogenous results due to the vast differences in the biology of various cancers. However, at the current state of knowledge, there is not enough information for a cancer type-specific assessment. Additionally, our review did not consider in detail possible toxicity issues resulting from supra-supplementation but rather evaluated safety at typically recommended doses. Lastly, due to the relatively recent onset of the COVID-19 pandemic, there are limited clinical trials on the efficacy of nutraceuticals for SARS-CoV-2. As a result, data on only a limited number of nutraceuticals could be identified. As more research becomes available, it is possible that more nutraceuticals will be deemed efficacious, and an updated safety review may become necessary.

5. Conclusions

Patients with cancer are one of several co-morbid populations who are at increased risk of a severe course of disease if infected with COVID-19. While a number of nutraceuticals have attracted interest due to their potential “anti-COVID-19” activity, there is concern about the safety of their usage in patients with cancer due to the potential interactions with their treatment regimen and possible associations with an increased risk of recurrence, cancer incidence, or even death.

This review highlights the heterogeneity of results regarding the safety of nutraceuticals for patients with cancer. It is conceivable that a large part of this heterogeneity is due to different types and stages of cancer, different treatments, and different clinical settings among the identified studies. Our findings indicate that vitamin D, vitamin C, and selenium supplementation are likely safe at normal doses (i.e., the dosages typically recommended for the general population). However, caution should be used with omega-3 fatty acid supplementation due to a conflict in the results between two long-term studies and a paucity of data overall. Similarly, zinc supplementation should probably be avoided due to a lack of relevant studies and because the currently available evidence indicates potential for harm or discomfort in patients with cancer.

Overall, this work emphasizes a sizeable gap in the literature surrounding the safety of nutraceuticals in patients with cancer and underscores the potential danger of liberal use of supplements by this high-risk group. Furthermore, this review provides important and immediately relevant clinical guidance for cancer care practitioners during an ongoing public health crisis. It is important to note that any supplement intake by patients with cancer should be discussed with their healthcare team so their providers may more accurately monitor their health and assess potential risks. Lastly, though early evidence indicates a potential benefit of some nutraceuticals against COVID-19, and thus potentially to high-risk cancer populations, we do not recommend supplementation as a substitute for regular medical care and a balanced diet.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13236094/s1, Table S1. References supporting nutraceutical use against COVID-19.

Author Contributions: K.S.B.-L. and E.A.L. contributed equally to the work reported. They were both involved in study conceptualization, data extraction, analysis, methodology, visualization, and writing the original draft. M.D. was involved in reviewing and editing the manuscript. F.M. was involved in study conceptualization, data extraction, methodology, supervision, visualization, and writing—review and editing. All authors have read and agreed to the published version of the manuscript.
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. WHO. WHO-Convened Global Study of Origins of SARS-CoV-2: China Part; Online; World Health Organization: Geneva, Switzerland, 2021.
2. WHO. Timeline: WHO’s COVID-19 Response. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline (accessed on 1 November 2021).
3. WHO. Novel Coronavirus (2019-nCoV): Situation Report 10. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200130-sitrep-10-ncov.pdf?sfvrsn=d0b2e480_2 (accessed on 1 November 2021).
4. WHO. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 1 November 2021).
5. CDC. Symptoms of COVID-19. Available online: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (accessed on 1 November 2021).
6. Song, P.; Li, W.; Xie, J.; Hou, Y.; You, C. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta 2020, 509, 280–287. [CrossRef]
7. Di Salvo, E.; Di Gioacchino, M.; Tonacci, A.; Casciato, M.; Gangemi, S. Alarmins, Viruses and COVID-19 and comorbidities. Ann. Med. 2021, 53, 777–785. [CrossRef] [PubMed]
8. Ejaz, H.; Alshami, A.; Zafar, A.; Javed, H.; Junaid, K.; Abdalla, A.E.; Abosalif, K.O.A.; Ahmed, Z.; Younas, S. COVID-19 and comorbidities: Deleterious impact on infected patients. J. Infect. Public Health 2020, 13, 1833–1839. [CrossRef]
9. Liang, W.; Guan, W.; Chen, R.; Wang, W.; Li, J.; Xu, K.; Li, C.; Ai, Q.; Lu, W.; Liang, H.; et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020, 21, 335–337. [CrossRef]
10. Miyashita, H.; Mikami, T.; Chopra, N.; Yamada, T.; Chernyavsky, S.; Rizk, D.; Cruz, C. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann. Oncol. 2020, 31, 1088–1089. [CrossRef] [PubMed]
11. Dalamaga, M.; Christodoulatos, G.S.; Karampela, I.; Vallianou, N.; Apovian, C.M. Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives. Curr. Obes. Rep. 2021, 10, 214–243. [CrossRef]
12. Lin, M.; Dong, H.Y.; Xie, H.Z.; Li, Y.M.; Jia, L. Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions. Drug Discov. Today 2021, 26, 631–636. [CrossRef]
13. Gunalan, E.; Cebioglu, I.K.; Conak, O. The Popularity of the Biologically-Based Therapies During Coronavirus Pandemic Among the Google Users in the USA, UK, Germany, Italy and France. Complement. Ther. Med. 2021, 58, 102682. [CrossRef]
14. Pereira, M.; Dantas Damascena, A.; Galvao Azevedo, L.M.; de Almeida Oliveira, T.; da Mota Santana, J. Vitamin D deficiency aggravates COVID-19: Systematic review and meta-analysis. Crit. Rev. Food Sci. Nutr. 2020, 1–9. [CrossRef] [PubMed]
15. Moghaddam, A.; Heller, R.A.; Sun, Q.; Seelig, J.; Cherkezov, A.; Seibert, L.; Hackler, J.; Seemann, P.; Diegmann, J.; Pilz, M.; et al. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. Nutrients 2020, 12, 2098. [CrossRef]
16. Vassiliou, A.G.; Jahaj, E.; Orfanos, S.E.; Dimopoulou, I.; Kotanidou, A. Vitamin D in infectious complications in critically ill patients with or without COVID-19. Metab. Open 2021, 11, 100106. [CrossRef] [PubMed]
17. Lordan, R.; Rando, H.M.; Consortium, C.-R.; Greene, C.S. Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment. mSystems 2021, 6, e00122-21. [CrossRef] [PubMed]
18. Corrao, S.; Mallacci Bocchio, R.; Lo Monaco, M.; Natoli, G.; Cavezzi, A.; Troiani, E.; Argano, C. Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of COVID-19 Prevention and Treatment. mSystems 2021, 6, e01221-21. [CrossRef] [PubMed]
19. Shakoor, H.; Feehan, J.; Al Dhaheri, A.; Ali, H.I.; Platat, C.; Skog, A.; Ursin, G.; Helland, A. COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study from Norway. Front. Oncol. 2021, 11, 652535. [CrossRef]
26. Kuderer, N.M.; Choueiri, T.K.; Shah, D.P.; Shyr, Y.; Rubinstein, S.M.; Rivera, D.R.; Shete, S.; Hsu, C.Y.; Desai, A.; de Lima Lopes, G., Jr.; et al. Clinical impact of COVID-19 on patients with cancer (C CCC19): A cohort study. *Lancet* **2020**, *395*, 1907–1918. [CrossRef]

27. Pathania, A.S.; Prathipati, P.; Abdul, B.A.; Chava, S.; Katta, S.S.; Gupta, S.C.; Ganga, P.R.; Pandey, M.K.; Durden, D.L.; Byrareddy, S.N.; et al. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. *Theranostics* **2021**, *11*, 731–753. [CrossRef]

28. Wu, M.Y.; Li, C.J.; Yang, G.T.; Cheng, Y.L.; Tsai, A.P.; Hou, Y.T.; Ho, Y.C.; Hou, M.F.; Chu, P.Y. Molecular Regulation of Bone Metastasis Pathogenesis. *Cell Physiol. Biochem.* **2018**, *46*, 1423–1438. [CrossRef]

29. Bandinelli, L.; Ornell, F.; von Diemen, L.; Kessler, F.H.P. The Sum of Fears in Cancer Patients Inside the Context of the COVID-19. *Front. Psychiatry* **2021**, *12*, 557834. [CrossRef] [PubMed]

30. Hamulka, J.; Jeruszka-Bielak, M.; Gornicka, M.; Drywien, M.E.; Zielinska-Pukos, M.A. Dietary Supplements during COVID-19 Outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. *Nutrients* **2020**, *13*, 54. [CrossRef]

31. 15 Best Supplements to Boost Your Immune System Right Now. Available online: https://www.healthline.com/nutrition/immune-boosting-supplements (accessed on 4 October 2021).

32. 20 Vitamins and Supplements to Boost Immune Health for COVID-19. Available online: https://www.medicinenet.com/covid_19_supplements/article.htm (accessed on 1 November 2021).

33. Aysin, E.; Urhan, M. Dramatic Increase in Dietary Supplement Use during COVID-19. *Curr. Dev. Nutr.* **2021**, *5*, 207. [CrossRef]

34. Ambrosone, C.B.; Zirpoli, G.R.; Hutson, A.D.; McCann, W.E.; McCann, S.E.; Barlow, W.E.; Kelly, K.M.; Cannioto, R.; Sucheston, Klapdor, S.; Richter, E.; Klapdor, R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. *Anticancer Res.* **2017**, *37*, 529–537. [PubMed]

35. Du, C.; Yang, S.; Zhao, X.; Dong, H. Pathogenic roles of alterations in vitamin D and vitamin D receptor in gastric tumorigenesis. *Cell Physiol. Biochem.* **2018**, *46*, 1423–1438. [CrossRef]

36. Bjelakovic, G.; Nikolova, D.; Simonetti, R.G.; Gluud, C. Vitamin D supplementation for preventing gastrointestinal cancers. *Cochrane Database Syst. Rev.* **2008**, CD004183. [CrossRef]

37. Bjelakovic, G.; Gluud, L.; Nikolova, D.; Whitfield, K.; Winterslev, J.; Simonetti, R.G.; Bjelakovic, M.; Gluud, C. Antioxidant supplements for preventing gastrointestinal cancers. *Cochrane Database Syst. Rev.* **2012**, *9*, CD004183. [CrossRef]

38. Campbell, R.A.; Li, J.; Malone, L.; Levy, D.A. Correlative Analysis of Vitamin D and Omega-3 Fatty Acid Intake in Men on Active Surveillance for Prostate Cancer. *Urology* **2021**, *155*, 110–116. [CrossRef] [PubMed]

39. Chen, F.; Du, M.; Blumberg, J.B.; Ho Chui, K.K.; Ruan, M.; Rogers, G.; Zeng, L.; Zhang, F.F. Association Among Dietary Vitamin D, Calcium, and Ovarian Cancer Risk. *Gynecol. Oncol.* **2018**, *155*, 79–85. [CrossRef] [PubMed]

40. Chen, F.; Du, M.; Blumberg, J.B.; Ho Chui, K.K.; Ruan, M.; Rogers, G.; Shyr, Y.; Chu, P.Y. Molecular Regulation of Bone Metastasis Pathogenesis. *Cell Physiol. Biochem.* **2018**, *46*, 1423–1438. [CrossRef]

41. Campbell, R.A.; Li, J.; Malone, L.; Levy, D.A. Correlative Analysis of Vitamin D and Omega-3 Fatty Acid Intake in Men on Active Surveillance for Prostate Cancer. *Urology* **2021**, *155*, 110–116. [CrossRef] [PubMed]

42. Chowdhury, R.; Kunutsor, S.; Vitezova, A.; Oliver-Williams, C.; Chowdhury, S.; Kiefte-de-Jong, J.C.; Khoo, H.; Baena, C.P.; Prabhakaran, D.; Hoshen, M.B.; et al. Effect of Vitamin D Supplementation on Mortality in United Kingdom: Observational Study. *BMJ* **2017**, *359*, j5052. [CrossRef] [PubMed]

43. Cook, L.E.; Hershman, D.L.; et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0219). J. Clin. Oncol. **2020**, *38*, 804–814. [CrossRef] [PubMed]

44. Chlebowski, R.T. Vitamin D and breast cancer incidence and outcome. *Anticancer Agents Med. Chem.* **2013**, *13*, 98–106. [CrossRef]

45. Chowdhury, R.; Kunutsor, S.; Vitezova, A.; Oliver-Williams, C.; Chowdhury, S.; Kiefte-de-Jong, J.C.; Khan, H.; Baena, C.P.; Prabhakaran, D.; Hoshen, M.B.; et al. Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomised intervention studies. *BMJ* **2014**, *348*, g1903. [CrossRef]

46. Cook, L.S.; Neilson, H.K.; Lorenzetti, D.L.; Lee, R.C. A systematic literature review of vitamin D and ovarian cancer. *Am. J. Obstet. Gynecol.* **2010**, *203*, 70.e1–70.e8. [CrossRef]

47. Datta, M.; Schwartz, G.G. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: A critical review. *Oncologist* **2012**, *17*, 1171–1179. [CrossRef] [PubMed]

48. Du, C.; Yang, S.; Zhao, X.; Dong, H. Pathogenic roles of alterations in vitamin D and vitamin D receptor in gastric tumorigenesis. *Oncotarget* **2017**, *8*, 29474–29486. [CrossRef] [PubMed]

49. Grant, W.B.; Boucher, B.J. A Review of the Potential Benefits of Increasing Vitamin D Status in Mongolian Adults through Food Fortification and Vitamin D Supplementation. *Nutrients* **2019**, *11*, 2452. [CrossRef]

50. Harvie, M. Nutritional supplements and cancer: Potential benefits and proven harms. *Am. Soc. Clin. Oncol. Educ. Book* **2014**, *34*, e478–e486. [CrossRef]

51. Holm, M.; Olsen, A.; Kroman, N.; Tjonneland, A. Lifestyle influences on the association between pre-diagnostic hormone replacement therapy and breast cancer prognosis—Results from The Danish ‘Diet, Cancer and Health’ prospective cohort. *Maturitas* **2014**, *79*, 442–448. [CrossRef] [PubMed]

52. Kanellopoulou, A.; Riza, E.; Samoli, E.; Benetou, V. Dietary Supplement Use after Cancer Diagnosis in Relation to Total Mortality, Cancer Mortality and Recurrence: A Systematic Review and Meta-Analysis. *Nutr. Cancer* **2021**, *73*, 16–30. [CrossRef] [PubMed]

53. Khan, Q.; Kimler, B.F.; Reddy, P.S.; Sharma, P.; Klemm, J.R.; Nydegger, J.L.; Yeh, H.W.; Fabian, C.J. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. *Breast Cancer Res. Treat.* **2017**, *166*, 491–500. [CrossRef]

54. Klapdor, S.; Richter, E.; Klapdor, R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. *Anticancer Res.* **2012**, *32*, 1991–1998. [PubMed]
52. Lewis, C.; Xun, P.; He, K. Vitamin D supplementation and quality of life following diagnosis in stage II colorectal cancer patients: A 24-month prospective study. *Support. Care Cancer* 2016, 24, 1655–1661. [CrossRef] [PubMed]

53. Madden, J.M.; Murphy, L.; Zgaga, L.; Bennett, K. De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival. *Breast Cancer Res. Treat.* 2018, 172, 179–190. [CrossRef] [PubMed]

54. Martinez, M.E.; Jacobs, E.T.; Baron, J.A.; Marshall, J.R.; Byers, T. Dietary supplements and cancer prevention: Balancing potential benefits against proven harms. *J. Natl. Cancer Inst.* 2012, 104, 732–739. [CrossRef]

55. Morita, M.; Okuyama, M.; Akutsu, T.; Ohdaira, H.; Suzuki, Y.; Urashima, M. Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial. *Nutrients* 2021, 13, 1687. [CrossRef] [PubMed]

56. Mulpur, B.H.; Nabors, L.B.; Thompson, R.C.; Olson, J.J.; LaRocca, R.V.; Thompson, Z.; Egan, K.M. Complementary therapy and survival in glioblastoma. *Neuro Oncol. Pract.* 2015, 2, 122–126. [CrossRef]

57. Saquib, J.; Rock, C.L.; Natarajan, L.; Saquib, N.; Newman, V.A.; Patterson, R.E.; Thomson, C.A.; Al-DeLaimy, W.K.; Pierce, J.P. Dietary intake, supplement use, and survival among women diagnosed with early-stage breast cancer. *Nutr. Cancer* 2011, 63, 327–333. [CrossRef]

58. Sarre, S.; Maattanen, L.; Tammela, T.L.; Auvinen, A.; Murtola, T.J. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: Vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. *Scand. J. Urol.* 2016, 50, 267–273. [CrossRef] [PubMed]

59. Zhang, X.; Niu, W. Meta-analysis of randomized controlled trials on vitamin D supplement and cancer incidence and mortality. *Biosci. Rep.* 2019, 39, BSR20190369. [CrossRef] [PubMed]

60. Zirpoli, G.R.; McCann, S.E.; Suestechon-Campbell, L.E.; Hershman, D.L.; Ciupak, G.; Davis, W.; Unger, J.M.; Moore, H.C.F.; Stewart, J.A.; Isaacs, C.; et al. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (0221): The DELCaP Study. *J. Natl. Cancer Inst.* 2017, 109, dxj098. [CrossRef]

61. Bjelakovic, G.; Nikolova, D.; Simonetti, R.G.; Gluud, C. Systematic review: Primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. *Aliment. Pharmacol. Ther.* 2008, 28, 689–703. [CrossRef]

62. Jacobs, E.J.; Connell, C.J.; McCullough, M.L.; Jonas, C.R.; Rodriguez, C.; Calle, E.E.; Thun, M.J. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. *Am. J. Epidemiol.* 2002, 156, 1002–1010. [CrossRef]

63. Lin, J.; Cook, N.R.; Albert, C.; Zaharris, E.; Gaziano, J.M.; Van Denburgh, M.; Buring, J.E.; Manson, J.E. Vitamins C and E and beta carotene supplementation and cancer risk: A randomized controlled trial. *J. Natl. Cancer Inst.* 2009, 101, 14–23. [CrossRef] [PubMed]

64. Messerer, M.; Hakansson, N.; Wolk, A.; Akesson, A. Dietary supplement use and mortality in a cohort of Swedish women. *Br. J. Cancer* 2013, 109, 257–264. [CrossRef]

65. Harris, H.R.; Bergkvist, L.; Wolk, A. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. *Br. J. Cancer* 2013, 109, 257–264. [CrossRef]

66. Harris, H.R.; Orsini, N.; Wolk, A. Vitamin C and survival among women with breast cancer: A meta-analysis. *Eur. J. Cancer* 2014, 50, 1223–1231. [CrossRef]

67. Jacobs, E.J.; Connell, C.J.; McCullough, M.L.; Chao, A.; Jonas, C.R.; Rodriguez, C.; Calle, E.E.; Thun, M.J. Vitamin C, vitamin E, and multivitamin supplement use and stomach cancer mortality in the Cancer Prevention Study II cohort. *Cancer Epidemiol. Biomark. Prev.* 2002, 11, 35–41.

68. Jacobs, E.J.; Henion, A.K.; Briggs, P.J.; Connell, C.J.; McCullough, M.L.; Jonas, C.R.; Rodriguez, C.; Calle, E.E.; Thun, M.J. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. *Am. J. Epidemiol.* 2002, 156, 1002–1010. [CrossRef]

69. Lin, J.; Cook, N.R.; Albert, C.; Zaharris, E.; Gaziano, J.M.; Van Denburgh, M.; Buring, J.E.; Manson, J.E. Vitamins C and E and beta carotene supplementation and cancer risk: A randomized controlled trial. *J. Natl. Cancer Inst.* 2009, 101, 14–23. [CrossRef] [PubMed]

70. Messerer, M.; Hakansson, N.; Wolk, A.; Akesson, A. Dietary supplement use and mortality in a cohort of Swedish women. *Br. J. Nutr.* 2008, 99, 626–631. [CrossRef]

71. Jenkins, D.J.A.; Kitts, D.; Giovannucci, E.L.; Sahye-Pudaruth, S.; Paquette, M.; Blanco Mejia, S.; Patel, D.; Kavanagh, M.; Tsirakis, T.; Kendall, C.W.C.; et al. Selenium, antioxidants, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* 2020, 112, 1642–1652. [CrossRef]

72. Jiang, L.; Yang, K.H.; Tian, J.H.; Guan, Q.L.; Yao, N.; Cao, N.; Mi, D.H.; Wu, J.; Ma, B.; Yang, S.H. Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: A meta-analysis of randomized controlled trials. *Nutr. Cancer* 2010, 62, 719–727. [CrossRef] [PubMed]

73. Kenfield, S.A.; Van Blarigan, E.L.; DuPre, N.; Stampfer, M.J.; Giovannucci, E.L.; Chan, J.M. Selenium supplementation and prostate cancer mortality. *J. Natl. Cancer Inst.* 2015, 107, 360. [CrossRef] [PubMed]
75. Muecke, R.; Schomburg, L.; Glatzel, M.; Berndt-Skorka, R.; Baaske, D.; Reichl, B.; Buentzel, J.; Kundt, G.; Prott, F.J.; Devries, A.; et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. *Int. J. Radiat. Oncol. Biol. Phys.* 2010, 78, 828–835. [CrossRef] [PubMed]

76. Samuels, N.; Schiff, E.; Ben-Arye, E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: Creating a doctor-patient dialogue. *BMJ Support. Palliat. Care* 2014, 4, e1. [CrossRef]

77. Klassen, P.; Cervantes, M.; Mazurak, V.C. N-3 fatty acids during chemotherapy: Toward a higher level of evidence for clinical application. *Curr. Opin. Clin. Nutr. Metab. Care* 2020, 23, 82–88. [CrossRef]

78. Miyata, H.; Yano, M.; Yasuda, T.; Yamasaki, M.; Murakami, K.; Makino, T.; Nishiki, K.; Sugimura, K.; Motoori, M.; Shiraishi, O.; et al. Randomized study of the clinical effects of omega-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. *Nutrition* 2017, 33, 204–210. [CrossRef]

79. Shen, S.; Unger, J.M.; Crew, K.D.; Till, C.; Greenlee, H.; Gralow, J.; Dakhil, S.R.; Minasian, L.M.; Wade, J.L.; Fisch, M.J.; et al. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). *Breast Cancer Res. Treat.* 2018, 172, 603–610. [CrossRef]

80. Sorensen, L.S.; Rasmussen, S.L.; Calder, P.C.; Yilmaz, M.N.; Schmidt, E.B.; Thorlaciuss-Ussing, O. Long-term outcomes after perioperative treatment with omega-3 fatty acid supplements in colorectal cancer. *BJS Open* 2020, 4, 678–684. [CrossRef] [PubMed]

81. Vernieri, C.; Nichetti, F.; Raimondi, A.; Pusceddu, S.; Platania, M.; Berrino, F.; de Braud, F. Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. *Crit. Rev. Oncol. Hematol.* 2018, 123, 57–73. [CrossRef]

82. De Sousa, R.A.L.; Improta-Caria, A.C.; Aras-Junior, R.; de Oliveira, E.M.; Soci, U.P.R.; Cassilhas, R.C. Physical exercise effects on the brain during COVID-19 pandemic: Links between mental and cardiovascular health. *Neurol. Sci.* 2021, 42, 1325–1334. [CrossRef]

83. Wang, C.; Zhu, H.; Zhou, Y.; Mao, F.; Lin, Y.; Pan, B.; Zhang, X.; Xu, Q.; Huang, X.; Sun, Q. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. *Breast J.* 2017, 23, 436–443. [CrossRef]

84. Gu, L.; Chen, M.; Guo, D.; Zhu, H.; Zhang, W.; Pan, J.; Zhong, X.; Li, X.; Qian, H.; Wang, X. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. *PloS ONE 2017*, 12, e0182692. [CrossRef] [PubMed]

85. Vrankar, M.; Zwitter, M.; Kern, I.; Stanic, K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. *Neoplasma 2018*, 65, 140–146. [CrossRef] [PubMed]

86. Hu, Y.; Chen, W.; Yan, Z.; Ma, J.; Zhu, F.; Huo, J. Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis. *Medicine* 2019, 98, e14006. [CrossRef] [PubMed]

87. Hudson, K.; Cross, N.; Jordan-Mahy, N.; Leyland, R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. *Front. Immunol.* 2020, 11, 568931. [CrossRef]

88. de Sousa Melo, A.; de Lima Dantas, J.B.; Medrado, A.; Lima, H.R.; Martins, G.B.; Carrera, M. Nutritional supplements in the management of oral mucositis in patients with head and neck cancer: Narrative literary review. *Clin. Nutr. ESPEN 2021*, 43, 31–38. [CrossRef] [PubMed]

89. Kieliszek, M.; Lipinski, B. Selenium supplementation in the prevention of coronavirus infections (COVID-19). *Med. Hypotheses 2020*, 143, 109878. [CrossRef] [PubMed]

90. Pal, A.; Squitti, R.; Picozza, M.; Pawar, A.; Rongioletti, M.; Dutta, A.K.; Sahoo, S.; Goswami, K.; Sharma, P.; Prasad, R. Zinc and COVID-19: Basis of Current Clinical Trials. *Biol. Trace Elem. Res.* 2021, 199, 2882–2892. [CrossRef] [PubMed]